# Upifitamab rilsodotin

Source: https://onco.cc/drugs/upifitamab-rilsodotin/  
OnCo record `upifitamab-rilsodotin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Upifitamab rilsodotin is an antibody-drug conjugate from Mersana Therapeutics, in registered phase 2 trials for ovarian cancer, non-small-cell lung cancer.

## Summary

Upifitamab rilsodotin is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Mersana Therapeutics, in ovarian cancer, non-small-cell lung cancer. An antibody-drug conjugate: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. The registry record does not state the target or payload; the trial entries below carry the sponsor's description. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: XMT-1536; UpRi
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Antibody-drug conjugate
- Mechanism: An antibody-drug conjugate: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. The registry record does not state the target or payload; the trial entries below carry the sponsor's description.

## Sources

- ClinicalTrials.gov: trials of Upifitamab rilsodotin: https://clinicaltrials.gov/search?intr=Upifitamab%20rilsodotin

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Mersana Therapeutics](https://onco.cc/companies/mersana/)
- trials: [First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b](https://onco.cc/trials/nct03319628/)

---
JSON: https://onco.cc/api/v1/entities/upifitamab-rilsodotin.json